Incorporating newer agents in the treatment of acute myeloid leukemia. Leuk Res 2018 Nov;74:113-120
Date
11/08/2018Pubmed ID
30401522DOI
10.1016/j.leukres.2018.10.008Scopus ID
2-s2.0-85055577100 (requires institutional sign-in at Scopus site) 9 CitationsAbstract
Prognosis for patients with AML remains dismal. Despite multiple clinical trials across several decades, little improvement for the therapy of non-APL AML was noted. However, over the last couple of years, several new therapies have demonstrated efficacy in the therapy of patients with AML. Several of those have been approved by the FDA for AML therapy. These include CPX-351, midostaurin, gemtuzumab ozogamicin, enasidenib and ivosidenib. Our goal in this review is to summarize currently available data on these new therapies and discuss the rapidly evolving treatment landscape of AML.
Author List
Raj RV, Abedin SM, Atallah EAuthors
Sameem Abedin MD Associate Professor in the Medicine department at Medical College of WisconsinEhab L. Atallah MD Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Antineoplastic AgentsDrug Approval
Female
Humans
Leukemia, Myeloid, Acute
Male
United States
United States Food and Drug Administration